Concarlo Therapeutics is a preclinical oncology biotech developing transformative therapeutics to target drug-resistant cancers. Concarlo’s vision is to create a world of possibility and time, where cancer is a treatable, manageable, and survivable condition.
In oncology, precision medicine has produced many therapies, but resistance, due to downstream activation of targets remains a critical unmet need. Concarlo is addressing this challenge by targeting protein p27, the direct inhibitor of CDK4/CDK6, and CDK2, which are highly validated targets with already-marketed drugs. Concarlo is leveraging this natural pathway to inhibit CDK4/6 and CDK2 in concert, which has not been done successfully by previous standards of care due to high toxicity.
As p27 inhibition extends to multiple tumor types, our first indications will be in HR+/HER2- metastatic breast cancer, ovarian cancer, uterine cancer and NSCLC – with potential in additional tumor types to be explored through ongoing stud
In oncology, precision medicine has produced many therapies, but resistance, due to downstream activation of targets remains a critical unmet need. Concarlo is addressing this challenge by targeting protein p27, the direct inhibitor of CDK4/CDK6, and CDK2, which are highly validated targets with already-marketed drugs. Concarlo is leveraging this natural pathway to inhibit CDK4/6 and CDK2 in concert, which has not been done successfully by previous standards of care due to high toxicity.
As p27 inhibition extends to multiple tumor types, our first indications will be in HR+/HER2- metastatic breast cancer, ovarian cancer, uterine cancer and NSCLC – with potential in additional tumor types to be explored through ongoing stud
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
New York
Company HQ Country:
United States
Year Founded:
2017
Main Therapeutic Focus:
Oncology
Lead Product in Development:
Our lead p27 inhibitor, IPY, is a synthetically produced peptide based on the natural p27 agonist.
Development Phase of Primary Product:
Pre-Clinical
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
